Faculty of Life Sciences, The University of Manchester, Manchester, M13 9PT, UK.
Pharmacogenomics. 2010 Nov;11(11):1545-60. doi: 10.2217/pgs.10.125.
Glucocorticoid hormones are used extensively in the clinic for the treatment of acute lymphoblastic leukemia. Despite intensive research, the molecular mechanisms of glucocorticoid receptor (GR)-mediated transcriptional events that lead to the induction of apoptosis of leukemia cells, as well as the causes for the development of resistance in leukemia patients, are not yet understood. It is thought that the B-cell lymphoma 2 family members that control apoptosis, including some of the GR target genes, may play an important role in deciding cell fate. In this report we have employed pathway modeling due to the recent discovery of its usefulness as a tool for improving understanding of the mechanisms of cellular signaling, and in discovering new therapeutic targets for the treatment of various diseases.
MATERIALS & METHODS: Detailed kinetics of GR autoregulation, as well as the kinetics of expression of its target genes and proteins Bcl-xL, Bim, Bmf and GILZ in glucocorticoid responsive and resistant leukemia cell lines were carried out. Subsequently in order to obtain further insight into the molecular mechanisms of GR signaling in this pathway a dynamic model of the induction of these genes and proteins by GR was constructed.
The simulations were in good agreement with the observed experimental data suggesting that Bim was induced between 6 and 10 h after the addition of the synthetic glucocorticoid dexamethasone, possibly through rapid glucocorticoid dependent modulation of an unknown factor. Simulations and experimental results also suggested that Bmf induction did not require novel protein synthesis, and is a potential direct GR target.
This combination of experimental analysis and model development initiates a virtuous cycle enabling further data integration and model expansion, and constitutes a novel promising framework towards a global mechanistic understanding of GR function.
糖皮质激素在临床上被广泛用于治疗急性淋巴细胞白血病。尽管进行了深入的研究,但糖皮质激素受体(GR)介导的转录事件导致白血病细胞凋亡的分子机制,以及白血病患者产生耐药性的原因,仍未被理解。人们认为,控制细胞凋亡的 B 细胞淋巴瘤 2 家族成员,包括一些 GR 靶基因,可能在决定细胞命运方面发挥重要作用。在本报告中,我们采用了途径建模,因为最近发现它是一种有用的工具,可以帮助我们更好地理解细胞信号转导的机制,并发现治疗各种疾病的新治疗靶点。
详细研究了 GR 自身调节的动力学,以及其靶基因和蛋白质 Bcl-xL、Bim、Bmf 和 GILZ 在糖皮质激素反应性和耐药性白血病细胞系中的表达动力学。随后,为了进一步了解 GR 信号通路中的分子机制,构建了 GR 诱导这些基因和蛋白质表达的动态模型。
模拟结果与观察到的实验数据吻合较好,表明在添加合成糖皮质激素地塞米松后 6 至 10 小时内诱导了 Bim,可能是通过快速的糖皮质激素依赖性调节未知因子。模拟和实验结果还表明,Bmf 的诱导不需要新的蛋白质合成,并且可能是一个潜在的直接 GR 靶标。
这种实验分析和模型开发的结合,开启了一个良性循环,能够进一步进行数据整合和模型扩展,为全面理解 GR 功能提供了一个新的有前途的框架。